Bukwang Pharm Asset Resilience Ratio
Bukwang Pharm asset resilience ratio. Bukwang Pharm (003000) has an Asset Resilience Ratio of 39.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Bukwang Pharm to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bukwang Pharm (2007–2024)
Asset resilience ratio of Bukwang Pharm from 2007 to 2024. This chart shows how Bukwang Pharm's Asset Resilience Ratio has changed over time. Read 003000 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bukwang Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 003000 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩188.03 Billion | 39.75% |
| Total Liquid Assets | ₩188.03 Billion | 39.75% |
Asset Resilience Insights
- Very High Liquidity: Bukwang Pharm maintains exceptional liquid asset reserves at 39.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Bukwang Pharm Industry Peers by Asset Resilience Ratio
Compare Bukwang Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Bukwang Pharm Asset Resilience Ratio by Year (2007–2024)
Bukwang Pharm asset resilience ratio by year from 2007 to 2024. The table below shows the annual Asset Resilience Ratio data for Bukwang Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 10.72% | ₩40.00 Billion ≈ $27.11 Million |
₩373.18 Billion ≈ $252.90 Million |
+10.34pp |
| 2021-12-31 | 0.38% | ₩1.50 Billion ≈ $1.02 Million |
₩397.42 Billion ≈ $269.32 Million |
-2.19pp |
| 2020-12-31 | 2.57% | ₩10.30 Billion ≈ $6.98 Million |
₩400.97 Billion ≈ $271.73 Million |
-3.95pp |
| 2014-12-31 | 6.51% | ₩15.43 Billion ≈ $10.46 Million |
₩236.82 Billion ≈ $160.49 Million |
-2.28pp |
| 2013-12-31 | 8.79% | ₩20.07 Billion ≈ $13.60 Million |
₩228.21 Billion ≈ $154.66 Million |
+3.73pp |
| 2008-12-31 | 5.06% | ₩11.67 Billion ≈ $7.91 Million |
₩230.55 Billion ≈ $156.24 Million |
-8.07pp |
| 2007-12-31 | 13.13% | ₩28.24 Billion ≈ $19.14 Million |
₩215.02 Billion ≈ $145.71 Million |
-- |
About Bukwang Pharm
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more